Constitutively Active CCR5 Chemokine Receptors Differ in Mediating HIV Envelope-dependent Fusion

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  de Voux, Alex ^a,c   Chan, Mei Chi ^a   Folefoc, Asongna T ^a,d   Madziva, Michael T ^b   Flanagan, Colleen A ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; CHEMOKINE RECEPTOR CCR5; GLUTAMINE; INOSITOL PHOSPHATE; LYSINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROLINE; THREONINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MEMBRANE FUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; VIRUS ENVELOPE; VIRUS MUTANT;

AMINO ACID SUBSTITUTION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV-1; HUMANS; MUTATION, MISSENSE; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84872766968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054532     Document Type: Article

References (64)

1. Oppermann M, (2004) Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 16: 1201-1210.
2. Lederman MM, Penn-Nicholson A, Cho M, Mosier D, (2006) Biology of CCR5 and its role in HIV infection and treatment. JAMA 296: 815-826.
3. Kenakin T, (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42: 349-379.
4. Deupi X, Kobilka BK, (2010) Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25: 293-303.
5. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, et al. (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187: 1215-1224.
6. Freedman BD, Liu QH, Del Corno M, Collman RG, (2003) HIV-1 gp120 chemokine receptor-mediated signaling in human macrophages. Immunol Res 27: 261-276.
7. Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, et al. (1997) Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389: 981-985.
8. Wu Y, Yoder A, (2009) Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 5: e1000520.
9. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289: 739-745.
10. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
11. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
12. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. (2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
13. Choe HW, Kim YJ, Park JH, Morizumi T, Pai EF, et al. (2011) Crystal structure of metarhodopsin II. Nature 471: 651-655.
14. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, et al. (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-502.
15. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
16. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, et al. (2009) A G protein-coupled receptor at work: the rhodopsin model. Trends Biochem Sci 34: 540-552.
17. Ahuja S, Smith SO, (2009) Multiple switches in G protein-coupled receptor activation. Trends Pharmacol Sci 30: 494-502.
18. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW, (2009) Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30: 249-259.
19. Flanagan CA, (2005) A GPCR that is not "DRY". Mol Pharmacol 68: 1-3.
20. Govaerts C, Blanpain C, Deupi X, Ballet S, Ballesteros JA, et al. (2001) The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem 276: 13217-13225.
21. Arias DA, Navenot JM, Zhang WB, Broach J, Peiper SC, (2003) Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. J Biol Chem 278: 36513-36521.
22. Folefoc AT, Fromme BJ, Katz AA, Flanagan CA, (2010) South African mutations of the CCR5 coreceptor for HIV modify interaction with chemokines and HIV Envelope protein. J Acquir Immune Defic Syndr 54: 352-359.
23. Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou CL, et al. (1997) Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A 94: 5061-5066.
24. Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, et al. (1997) HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem 272: 6854-6857.
25. Amara A, Vidy A, Boulla G, Mollier K, Garcia-Perez J, et al. (2003) G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol 77: 2550-2558.
26. Buontempo PJ, Wojcik L, Buontempo CA, Ogert RA, Strizki JM, et al. (2009) Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor. Virology 395: 268-279.
27. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, et al. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81: 2359-2371.
28. Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, et al. (2010) HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 26: 13-24.
29. Moore JP, Kuritzkes DR, (2009) A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 4: 118-124.
30. Kostenis E, (2001) Is Galpha16 the optimal tool for fishing ligands of orphan G-protein- coupled receptors? Trends Pharmacol Sci 22: 560-564.
31. Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, et al. (2006) Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 87: 399-410.
32. Jenkinson S, McCoy D, Kerner S, Ferris R, Lawrence W, et al. (2003) Development of a high-throughput viral-free assay for the measurement of CCR5-mediated HIV/cell fusion. Receptors Channels 9: 117-123.
33. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
34. Ballesteros J, Weinstein W, (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25: 366-428.
35. Millar RP, Davidson J, Flanagan C, Wakefield I, (1995) Ligand Binding and Second-Messenger Assays for Cloned Gq/G11-Coupled Neuropeptide Receptors: The GnRH Receptor. Methods in Neuroscience 25: 145-162.
36. Flanagan CA, Fromme BJ, Davidson JS, Millar RP, (1998) A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology 139: 4115-4119.
37. Fromme BJ, Coetsee M, Van Der Watt P, Chan MC, Sperling KM, et al. (2008) High-affinity binding of southern African HIV type 1 subtype C envelope protein, gp120, to the CCR5 coreceptor. AIDS Res Hum Retroviruses 24: 1527-1536.
38. Reynes J, Portales P, Segondy M, Baillat V, Andre P, et al. (2000) CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 181: 927-932.
39. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
40. Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, et al. (2008) Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci U S A 105: 17706-17711.
41. Doms RW, (2000) Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276: 229-237.
42. Lin YL, Mettling C, Portales P, Reynes J, Clot J, et al. (2002) Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 99: 15590-15595.
43. Samama P, Cotecchia S, Costa T, Lefkowitz RJ, (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625-4636.
44. Milligan G, Bond RA, (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18: 468-474.
45. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, et al. (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272: 2587-2590.
46. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA, et al. (1999) Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 56: 175-184.
47. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, et al. (2000) The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. Mol Pharmacol 57: 890-898.
48. Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, et al. (2011) Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). J Biol Chem 286: 33409-33421.
49. Deupi X, Standfuss J, (2011) Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr Opin Struct Biol 21: 541-551.
50. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, et al. (2012) Action of molecular switches in GPCRs-theoretical and experimental studies. Curr Med Chem 19: 1090-1109.
51. Rovati GE, Capra V, Neubig RR, (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959-964.
52. Lagane B, Ballet S, Planchenault T, Balabanian K, Le Poul E, et al. (2005) Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol Pharmacol 67: 1966-1976.
53. Springael JY, de Poorter C, Deupi X, Van Durme J, Pardo L, et al. (2007) The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin. Cell Signal 19: 1446-1456.
54. Dalbey RE, (1990) Positively charged residues are important determinants of membrane protein topology. Trends Biochem Sci 15: 253-257.
55. Govaerts C, Bondue A, Springael JY, Olivella M, Deupi X, et al. (2003) Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J Biol Chem 278: 1892-1903.
56. Pei G, Samama P, Lohse M, Wang M, Codina J, et al. (1994) A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci U S A 91: 2699-2702.
57. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, et al. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277: 24515-24521.
58. Beinborn M, Ren Y, Blaker M, Chen C, Kopin AS, (2004) Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65: 753-760.
59. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, et al. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78: 8654-8662.
60. Watson C, Jenkinson S, Kazmierski W, Kenakin T, (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67: 1268-1282.
61. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E, (2002) Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 13: 336-343.
62. Vaidehi N, Kenakin T, (2010) The role of conformational ensembles of seven transmembrane receptors in functional selectivity. Curr Opin Pharmacol 10: 775-781.
63. Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, et al. (2011) New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 286: 4978-4990.
64. Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, et al. (2009) Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem 284: 31270-31279.